Clinical Trial Search

Primary: Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 72 — 54.84 percentage of participants

Primary: Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs) — 4; 8; 10; 0 Participants

Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 2 — 9.5; -0.4 letters — p=<0.001

Primary: Pathologic Complete Response (pCR) Rate in Patients Treated With ErC for 6 Cycles Prior to Surgery — 18; 10 percentage of surgical patients

Primary: Duration of Insertion Between Foley Catheter Groups With and Without a Stylette. — 1.72; 1.88; 6.55; 5.00 minutes — p=.70

Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005

Primary: Change From Baseline to End of Study — 64; 18.5 Percentage of participants

Primary: Number of Young Adults Who Received Any Dose of the HPV Vaccine During the Study Period — 8; 9; 3 participants — p=.36

Primary: Percentage of Responders — 69.1 percentage of treatment responders

Primary: The Zung Self-Rating Anxiety Scale Scores Before and After the Intervention — 36.4; 37.3; 32.1; 38.5 units on a scale(raw scores) — p=<0.001

Primary: Binary Restenosis — 22.8 percentage of patients

Primary: Kinematics Translations During Deep Knee Bend (DKB) Activity — -10.11; -13.15; -5.15; -4.93 mm

Primary: Percentage of Participants Maintaining Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Load Below the Level of Quantification (LOQ) Through Week 48 — 96.7; 99.5; 100.0…

Primary: Severity of Adhesions at the Retrosternal Site — 0; 31.3; 0; 37.5 percentage of participants

Primary: Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP). — 100; 100; 0; 91.7 percentage of participants — p=<0.0001